Evidence map›Paper›PMID 39240637›Full record

ArticleJournal of Alzheimer's disease : JAD2024

Path Integration Detects Prodromal Alzheimer's Disease and Predicts Cognitive Decline.

Haruo Hanyu, Yumi Koyama, Kazuki Umekida, Sadayoshi Watanabe, Hiroshi Matsuda, Riki Koike, Akihiko Takashima

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Haruo HanyuDementia Research Center, Tokyo General Hospital, Tokyo, Japan.
Yumi KoyamaDepartment of Rehabilitation, Tokyo General Hospital, Tokyo, Japan.
Kazuki UmekidaDepartment of Rehabilitation, Tokyo General Hospital, Tokyo, Japan.
Sadayoshi WatanabeDepartment of Neurosurgery, Tokyo General Hospital, Tokyo, Japan.
Hiroshi MatsudaDepartment of Biofunctional Imaging, Fukushima Medical University, Fukushima, Japan.
Riki KoikeLaboratory for Alzheimer's Disease, Department of Life Science, Faculty of Science, Gakushuin University, Tokyo, Japan.
Akihiko TakashimaLaboratory for Alzheimer's Disease, Department of Life Science, Faculty of Science, Gakushuin University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The entorhinal cortex is the very earliest involvement of Alzheimer's disease (AD). Grid cells in the medial entorhinal cortex form part of the spatial navigation system. Objective: We aimed to determine whether path integration performance can be used to detect patients with mild cognitive impairment (MCI) at high risk of developing AD, and whether it can predict cognitive decline. Methods: Path integration performance was assessed in 71 patients with early MCI (EMCI) and late MCI (LMCI) using a recently developed 3D virtual reality navigation task. Patients with LMCI were further divided into those displaying characteristic brain imaging features of AD, including medial temporal lobe atrophy on magnetic resonance imaging and posterior hypoperfusion on single-photon emission tomography (LMCI+), and those not displaying such features (LMCI-). Results: Path integration performance was significantly lower in patients with LMCI+than in those with EMCI and LMCI-. A significantly lower performance was observed in patients who showed progression of MCI during 12 months, than in those with stable MCI. Path integration performance distinguished patients with progressive MCI from those with stable MCI, with a high classification accuracy (a sensitivity of 0.88 and a specificity of 0.70). Conclusions: Our results suggest that the 3D virtual reality navigation task detects prodromal AD patients and predicts cognitive decline after 12 months. Our navigation task, which is simple, short (12-15 minutes), noninvasive, and inexpensive, may be a screening tool for therapeutic choice of disease-modifiers in individuals with prodromal AD.

Indexed as

Alzheimer DiseaseCognitive DysfunctionMagnetic Resonance ImagingProdromal SymptomsAgedAged, 80 and overDisease ProgressionEntorhinal CortexFemaleHumansMaleMiddle AgedNeuropsychological TestsSpatial NavigationTomography, Emission-Computed, Single-PhotonVirtual RealityAlzheimer’s diseasemild cognitive impairmentpath integrationprodromal Alzheimer’s diseaseprogressionvirtual reality

Identifiers

PMID39240637
PMCPMC11491996

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.